logo
Share SHARE
FONT-SIZE Plus   Neg

Genzyme Reports Additional Data From Phase III CARE-MS II Trial

Genzyme, a Sanofi company (SNY), on Tuesday reported additional data from the Phase III CARE-MS II trial.

Accumulation of disability was significantly slowed in patients with multiple sclerosis who were treated with alemtuzumab versus Rebif, as measured by the Expanded Disability Status Scale, a standard assessment of physical disability progression.

In addition, significant improvement in disability scores was observed in some patients treated with alemtuzumab from baseline and compared to patients treated with Rebif, suggesting a reversal of disability in these patients. In the trial, patients with pre-existing disability treated with alemtuzumab were more than twice as likely to experience a sustained reduction in disability than patients given Rebif.

Genzyme is developing alemtuzumab in multiple sclerosis in collaboration with Bayer HealthCare.

CARE-MS II was a randomized Phase III clinical trial comparing the investigational drug alemtuzumab to Rebif in patients with relapsing-remitting multiple sclerosis who had relapsed while on prior therapy. The company announced in November that results for the co-primary endpoints of the trial were highly statistically significant. Additional new data from the CARE-MS II study suggest that alemtuzumab provided significant improvement over Rebif across a number of imaging endpoints, consistent with the effects observed in the clinical endpoints. The company said it is on track to file for U.S. and EU approval of alemtuzumab in relapsing multiple sclerosis in the second quarter of 2012.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
International fashion house Guess?, Inc. said Tuesday after the markets closed that it swung to a first quarter profit, as better costs control helped offset an 8.4% drop in revenue. The company's quarterly earnings per share also came in above analysts' expectations, but its quarterly revenue fell short of analysts' forecast. United Airlines' flights were temporarily grounded on Tuesday morning due to a computer problem, leading to delays for passengers. Automakers on Tuesday reported mixed U.S. vehicle sales results for the month of May, which included the Memorial Day weekend but had one less selling day compared to the same month last year. General Motors Co. and FCA US, LLC each reported higher vehicle sales for the month, while Ford Motor Co. and Toyota Motor Corp. both reported declines.
comments powered by Disqus
RELATED NEWS
Trade SNY now with 
Follow RTT